RFG Advisory LLC Sells 15,980 Shares of Novo Nordisk A/S $NVO

RFG Advisory LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 29.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,988 shares of the company’s stock after selling 15,980 shares during the period. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,933,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in NVO. Franklin Resources Inc. grew its position in Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares in the last quarter. Capital International Investors grew its position in Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Boston Partners bought a new stake in Novo Nordisk A/S in the third quarter worth approximately $310,199,000. SG Americas Securities LLC grew its position in Novo Nordisk A/S by 2,101.5% in the third quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after acquiring an additional 2,274,925 shares in the last quarter. Finally, Clear Street Group Inc. bought a new stake in Novo Nordisk A/S in the third quarter worth approximately $56,378,000. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NVO. CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Nordea Equity Research cut shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q1 beat and guidance lift—Novo posted stronger?than?expected results and raised its 2026 outlook after Wegovy pill sales outperformed, which is the main driver of the stock rise. Novo Nordisk’s first-quarter profit beats forecasts
• Positive Sentiment: Oral Wegovy momentum—Prescriptions for the oral Wegovy pill surpassed 2 million since launch, prompting analysts and the company to lift sales/profit guidance and restoring investor confidence in growth prospects. A Look At Novo Nordisk Valuation After Oral Wegovy Success
• Positive Sentiment: Distribution expansion via Amazon—Amazon Pharmacy and One Medical kiosks will offer same?day delivery/pickup for Novo’s oral GLP?1s, reducing access friction and likely supporting prescription volume. Amazon Pharmacy Expands Access to New Ozempic® Pill
• Neutral Sentiment: Management pursuing M&A—CEO says Novo is actively seeking deals to broaden the pipeline; positive for long?term diversification but not an immediate earnings driver. Novo Nordisk actively seeking deals to expand pipeline
• Neutral Sentiment: Regulatory tailwinds possible—the FDA’s recent proposal could benefit leaders in the GLP?1 space, but policy details and timing remain uncertain. What the FDA’s Latest Proposal Means for Lilly, Novo, and Hims
• Negative Sentiment: Competitive & generic risk—analysts warn that Eli Lilly competition and the arrival of semaglutide generics (first seen in Canada and a threat internationally) could pressure pricing and international revenue over time. First Ozempic generics in Canada will be a test case for Novo Nordisk
• Negative Sentiment: Margin & pricing pressure—despite volume gains, U.S. pricing pressure and some margin compression were noted in Q1 commentary, keeping near?term profitability under scrutiny. Novo Nordisk: Mixed Q1 Does Not Break The Thesis

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $45.78 on Friday. The stock has a market cap of $204.39 billion, a P/E ratio of 10.75, a PEG ratio of 10.86 and a beta of 0.77. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $81.44. The company has a fifty day moving average price of $38.71 and a 200 day moving average price of $46.97. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 66.00%. The firm had revenue of $10.85 billion during the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.34 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.